EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC 4.0

Progression‐Free Survival 2 as a Potential Surrogate for Overall Survival in Glioblastoma: Insights From a Spanish Multicentric Cohort

Jesús Yaringaño, Oriol Mirallas, Víctor Navarro, Diego Gómez-Puerto, Gabriel Velilla, María Ángeles Vaz, Teresa Gorria, Álvaro Martínez-Monino, Ainhoa Hernández, María Aguado, Antonio Di Muzio, Daniel López Valbuena und 10 weitere

Cancer Medicine · 2026-04 · 15 (4)

DOI: 10.1002/cam4.71825 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer Medicine, online erschienen am 19.04.2026. Verfasst von Jesús Yaringaño und 21 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, Vall D'hebron University Hospital, Barcelona, Spain. Hauptthemen laut MEDLINE: Brain Neoplasms, Glioblastoma. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Fundació Privada Institut d'Oncologia Vall d'Hebron - Vall d'Hebron Institute of Oncology (VHIO).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In glioblastoma, first‐line treatment can influence subsequent treatment lines. Therefore, progression‐free survival 2 (PFS2), the time from initial randomization to progression on subsequent treatment or death, may better predict overall survival (OS) compared to PFS. However, this association needs validation in glioblastoma, particularly with novel targeted agents in early clinical trials.

Methods

Medical records of glioblastoma patients from a multicentric Spanish cohort with genomic profiling treated between 2018 to 2023 were analyzed. Correlations between OS and PFS or PFS2 were calculated using an iterative multiple imputation approach and time‐to‐event endpoints with Kaplan–Meier methods.

Results

We analyzed 405 patients. Median OS, PFS, and PFS2 were 25.4, 8.7 and 16.4 months, respectively. Correlation between OS‐PFS was 0.69 (95% CI, 0.62–0.75), whilst for OS‐PFS2 it was 0.83 (95% CI, 0.78–0.87). In patients who received targeted therapy, OS‐PFS correlation was 0.51 (95% CI, 0.02–0.81), whilst for OS‐PFS2, it was 0.72 (95% CI, 0.30–0.91). For patients with ESCAT tier I‐II molecular targets, OS‐PFS correlation was 0.69 (95% CI, 0.26–0.89), weaker than OS‐PFS2 (0.83 [95% CI, 0.29–0.97]). PFS2 also performed better than PFS in ESCAT III‐IV patients (0.80 [95% CI, 0.75–0.85] vs. 0.69 [95% CI, 0.61–0.75]) and in those without targetable alterations (0.86 [95% CI, 0.74–0.92] vs. 0.68 [95% CI, 0.51–0.80]).

Conclusions

Progression‐free survival 2 (PFS2) is a more robust surrogate for OS than PFS in glioblastoma, including patients receiving targeted therapies or without actionable targets. These findings support adoption of PFS2 as a candidate surrogate endpoint in glioblastoma, offering a balance between trial feasibility and meaningful survival outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain NeoplasmsGlioblastomaAdultAgedFemaleHumansMaleMiddle AgedKaplan-Meier EstimateProgression-Free SurvivalSpain

Stichwörter der Autor:innen

clinical trialglioblastomamolecular targeted therapyprogression‐free survivalsurrogate endpoint

Autor:innen und Institutionen

  • Medical Oncology Department, Vall D'hebron University Hospital, Barcelona, Spain.
  • Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Statistics Unit, Vall D'hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Neurology Department, Instituto de Investigación Sanitaria Hospital 12 de Octubre (i+12), Madrid, Spain.
  • Medical Oncology Department, Hospital Universitario Ramon y Cajal, Madrid, Spain.
  • Medical Oncology Department, Hospital Clinic of Barcelona, Barcelona, Spain.

Förderung

  • Fundació Privada Institut d'Oncologia Vall d'Hebron - Vall d'Hebron Institute of Oncology (VHIO)

Zitieren

APA

Yaringaño, J., Mirallas, O., Navarro, V., Gómez-Puerto, D., Velilla, G., Vaz, M. Á., Gorria, T., Martínez-Monino, Á., Hernández, A., Aguado, M., Di Muzio, A., Valbuena, D. L., Ruiz-Pace, F., González, M., Martínez-García, M., Villacampa, G., Balaña, C., Carles, J., Dienstmann, R., …, & Vieito, M. (2026). Progression‐Free Survival 2 as a Potential Surrogate for Overall Survival in Glioblastoma: Insights From a Spanish Multicentric Cohort. Cancer Medicine, 15(4). https://doi.org/10.1002/cam4.71825

Vancouver

Yaringaño J, Mirallas O, Navarro V, Gómez-Puerto D, Velilla G, Vaz MÁ, et al. Progression‐Free Survival 2 as a Potential Surrogate for Overall Survival in Glioblastoma: Insights From a Spanish Multicentric Cohort. Cancer Medicine. 2026;15(4). doi:10.1002/cam4.71825

BibTeX
@article{Yaringao2026,
  author = {Yaringaño, Jesús and Mirallas, Oriol and Navarro, Víctor and Gómez-Puerto, Diego and Velilla, Gabriel and Vaz, María Ángeles and Gorria, Teresa and Martínez-Monino, Álvaro and Hernández, Ainhoa and Aguado, María and Di Muzio, Antonio and Valbuena, Daniel López and Ruiz-Pace, Fiorella and González, Macarena and Martínez-García, María and Villacampa, Guillermo and Balaña, Carmen and Carles, Joan and Dienstmann, Rodrigo and Pineda, Estela and Sepúlveda, Juan Manuel and Vieito, María},
  title = {Progression‐Free Survival 2 as a Potential Surrogate for Overall Survival in Glioblastoma: Insights From a Spanish Multicentric Cohort},
  journal = {Cancer Medicine},
  year = {2026},
  volume = {15},
  number = {4},
  doi = {10.1002/cam4.71825}
}
Kostenlos starten →